PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/02, 37/36, C07K 7/10 | A1

(11) International Publication Number: WO 93/06845

(43) International Publication Date: 15 April 1993 (15.04.93)

(21) International Application Number: PCT/US92/08477

(22) International Filing Date: 9 October 1992 (09.10.92)

(30) Priority data:
773,098 10 October 1991 (10.10.91) US

(71)(72) Applicant and Inventor: PANG, Peter, K., T. [US/CA]; 52225 Range Road 232, 205 Carriage Lane, Sherwood Park, Alberta T8A 2A6 (CA).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)* : SHAN, Jie [CN/CA]; 10615-83 Avenue, #105, Edmonton, Alberta T6E 2E3 (CA).

(74) Agent: MURRAY, Robert, B.; Nikaido, Marmelstein, Murray & Oram, Metropolitan Square, Suite 330, G Street Lobby, 655 15th Street, N.W., Washington, DC 20005-5701 (US).

(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published
With international search report.

(54) Title: PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT $aa^{25,26,27}$ AND USE IN OSTEOPOROSIS TREATMENT

(57) Abstract

Analogues of bovine and human parathyroid hormone, wherein twenty-fifth, twenty-sixth and twenty-seventh positions of the natural hormone, Arg-Lys-Lys- each have been substituted with Ala, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val have been found to retain bone cell effect with minimal effects on blood pressure and smooth muscle, including cardiac muscle. It has further been found that this effect can be obtained by using a synthetic PTH containing only the first 34 amino acids of PTH, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh amino acids as described. These analogues of PTH also are effective in the treatment of osteoporosis and other bone diseases.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria
AU	Australia
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CS	Czechoslovakia
CZ	Czech Republic
DE	Germany
DK	Denmark
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IT	Italy
JP	Japan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
LI	Liechtenstein
LK	Sri Lanka
LU	Luxembourg
MC	Monaco
MG	Madagascar
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SK	Slovak Republic
SN	Senegal
SU	Soviet Union
TD	Chad
TG	Togo
UA	Ukraine
US	United States of America
VN	Viet Nam

PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT $aa^{25, 26, 27}$ AND USE IN OSTEOPOROSIS TREATMENT

FIELD OF THE INVENTION

This invention relates to analogues of parathyroid hormone which, by substitution at the twenty-fifth, twenty-six and twenty-seventh positions of natural parathyroid hormone, have been found to affect calcium change in bone cells without producing the typical effects of parathyroid hormone on systolic and diastolic blood pressure, the effects on smooth muscle relaxation, vascular smooth muscle calcium change as well as positive chronotropic and inotropic effects on the heart.

BACKGROUND OF THE INVENTION

Parathyroid hormone (hereinafter, PTH) is produced by the parathyroid gland and is involved in the control of calcium levels in blood. It is a hypercalcemic hormone, elevating blood calcium levels. PTH is a polypeptide and the amino acid sequences of bovine and human PTH are closely related. Only the residues at locations one, seven and sixteen differ between the two. Synthetic polypeptides containing the first thirty-four residues of PTH may be prepared using the method disclosed by Erickson and Merrifield, The Proteins, Neurath et al., Eds., Academic Press, New York, 1976, page 257, preferably as modified by the method of Hodges et al., Peptide Research, 1, 19 (1988).

When serum calcium is reduced to below a "normal" level, the parathyroid gland releases PTH and resorption of bone calcium and increased absorption of calcium from the intestine, as well as renal reabsorption of calcium, occur.

The antagonist of PTH is calcitonin, which acts to reduce the level of circulating calcium. PTH is known to stimulate osteoclasts and its activity requires the presence of

derivatives of vitamin D_3, especially 1,25-dihydroxycholecalciferol.

Intracellular calcium, particularly in the cells of the vascular system, has been shown to affect changes in vascular tension, as can be measured by changes in blood pressure. U.S. Patent Application 603,745 describes one method which has been discovered to regulate calcium uptake in vascular cells.

Osteoporosis is a progressive disease which is particularly characteristic of postmenopausal women, and results in the reduction of total bone mass. The sequelae frequently involve fractures of load-bearing bones and the physical degenerations characteristic of immobilizing injuries. Osteoporosis is associated with hyperthyroidism, hyperparathyroidism, Cushings syndrome and the use of certain steroidal drugs. Remedies historically have involved increase in dietary calcium, estrogen therapy and increased doses of vitamin D.

PTH has been used to treat osteoporosis. However, while the use of PTH is effective in the treatment of osteoporosis by diminishing the loss of bone mass, PTH may exhibit other undesired pharmalogical effects, such as hypotension and smooth muscle relaxation (e.g. relaxation of gastrointestinal organs, uterus, tracheal and vas deferens) as well as positive chronotropic and inotropic effects on the heart. The relaxation effects of PTH on smooth muscle as well as positive chronotropic and inotropic effects of PTH are described in Pang et al, Trends in Pharmacological Sciences, Vol. 7, No. 9, pp. 340-341 (September 1986).

U.S. Patent No. 4,771,124 discloses the property of bovine and human PTH analogues wherein Trp^{23} is substituted by amino acids phenylalanine, leucine, norleucine, valine, tyrosine, beta-naphtylalanine and alpha-naphtylalanine as a PTH antagonist. While it was suggested that these analogues might be useful in the treatment of osteoporosis, it was based on the analogues antagonistic action to PTH. Furthermore, there was no data to indicate the effectiveness these analogues on bone or other tissue. In addition, analogues with substituted at

Trp^{23} with leucine, phenylalanine or tyrosine would produce undesired secondary effects of smooth muscle relaxation, vascular smooth muscle calcium change as well as positive chronotropic and inotropic effects on the heart.

Because PTH is a peptide, topical administration would be the preferred method of administration. However, topical application of PTH or the aforementioned analogues which exhibit vasoactivity would likely produce an undesired local vascular reaction. This reaction could be potentially detrimental if, for example, nasal administration is employed.

It is one object of this invention to ameliorate bone loss while preventing smooth muscle relaxation as well as positive chronotropic and inotropic effects on the heart and without significantly changing blood pressure. It is another object of this invention to identify that portion of PTH which is responsible for calcium regulation and that portion which appears to be primarily related to control of blood pressure and smooth muscle action.

BRIEF SUMMARY OF THE INVENTION

Modification of either bovine or human PTH at each of the twenty-fifth, twenty-sixth and twenty-seventh amino acid positions to substitute for -arginine-lysine-lysine- either alanine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine produces substantially no change in systolic and diastolic blood pressure, substantially no change in muscle tension and substantially no change in the rate of contraction and the force of contraction of the heart as compared to native PTH. It also has been observed that the PTH analogue containing only the first thirty-four amino acids, with substitution at the twenty-fifth, twenty-sixth and twenty-seventh positions, is equally effective in the "osteo effect" without changing blood pressure or causing muscle relaxation or positive chronotropic and inotropic effects on the heart.

The analogues of the present invention should be effective in ameliorating bone loss while preventing smooth muscle relaxation as well as positive chronotropic and inotropic effects on the heart and without significantly changing blood pressure.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1a shows the structure of natural bovine PTH (SEQ ID NO:1).

Fig. 1b shows the structure of natural human PTH (SEQ ID NO:2).

Fig. 2 shows the structure of bPTH (1-34) with each of positions 25, 26 and 27 substituted with Xaa (SEQ ID NO:3).

Fig. 3 shows the structure of bPTH (1-34) with each of positions 25, 26 and 27 substituted with Ala (SEQ ID NO:4).

Fig. 4 shows the structure of hPTH (1-34) with each of positions 25, 26 and 27 substituted Xaa (SEQ ID NO:5).

Fig. 5 shows the structure of hPTH (1-34) with each of positions 25, 26 and 27 substituted Ala (SEQ ID NO:6).

Fig. 6 shows the structure of bPTH with each of positions 25, 26 and 27 substituted with Xaa (SEQ ID NO:7).

Fig. 7 shows the structure of bPTH with each of positions 25, 26 and 27 substituted with Ala (SEQ ID NO:8).

Fig. 8 shows the structure of hPTH with each of positions 25, 26 and 27 substituted with Xaa (SEQ ID NO:9).

Fig. 9 shows the structure of hPTH with each of positions 25, 26 and 27 substituted with Ala (SEQ ID NO:10).

Fig. 10 shows the effect of bPTH-(1-34) and its analogues on diastolic blood pressure of anesthetized Sprague-Dawley rats.

Fig. 11 shows the effect of bPTH-(1-34) and its analogues on systolic blood pressure of anesthetized Sprague-Dawley rats.

Fig. 12 shows the vasorelaxing effect of bPTH-(1-34) and its analogues on rat tail artery helical strip in vitro.

Fig. 13 shows the depolarizing concentrations of KCl which increased calcium ion levels in cultured osteoblasts. Drug 788 is an anti-osteoporotic agent which inhibits the KCl effect.

Figs. 14 a-d show the depolarizing concentrations of KCl which increased calcium levels in cultured osteoblasts. Addition of bPTH-(1-34) inhibits the KCl effect.

Fig. 15 shows the effect of Cs88 [bPTH-(1-34)] on the mean arterial blood pressure of anesthetized Sprague-Dawley rats.

Fig. 16 shows the dose-response relationship between Cs88 [bPTH-(1-34)] and the tension of rat tail artery helical strips precontracted with KCl, norepinephrine and AVP.

Fig. 17 shows the effect of Cs88 on $[Ca^{2+}]_i$ in cultured UMR osteoblast cells.

Fig. 18 shows the effect of Cs88 on $[Ca^{2+}]_i$ in cultured UMR cells.

Fig. 19 shows a comparison of the effect of Cs221 and Cs99 and bPTH on the mean arterial blood pressure of anesthetized Sprague-Dawley rats.

Fig. 20 shows the relation between the relaxation curves of Sprague-Dawley rat tail artery helical strips, precontracted with AVP when treated with Cs100, Cs99, Cs88, Cs117 and Cs221.

Fig. 21 shows a comparison between the effect of Cs221 and hPTH on the intracellular calcium uptake in the presence of KCl in UMR cells in culture.

Fig. 22 shows the effect of Cs221 on the intracellular calcium uptake in the presence of KCl in UMR cells in culture.

Fig. 23 shows the effect of Cs1001 on the intracellular calcium uptake in the presence of KCl in UMR cells in culture.

Fig. 24 shows the effect of Cs221 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.

Fig. 25 shows the effect of Cs2001 and Cs1001 on the contractility and contraction rate of right atrial tissue of Sprague-Dawley rats.

DETAILED DESCRIPTION OF THE INVENTION

There are at least two known catagories of functions for PTH. PTH is involved in calcium balance in the blood stream and controls both the amount of calcium uptake from the

gastrointestinal tract and the deposition and removal of calcium from bone. Calcium also has been found to be effective in the maintenance of blood pressure. Cox, J. Cardiovascular Pharmacology, Vol. 8 (1986), Supp. 8 S48. Control of calcium in the walls of blood vessels is a useful therapeutic regimen for controlling hypertension and calcium channel blockers, which prevent the introduction of calcium into cell walls, is a conventional therapy for hypertension. Needleman et al. in Goodman and Gilman's The Pharmacological Basis of Therapeutics, MacMillan, New York, (1985), page 816 ff.

Administration of therapeutic doses of PTH has been found to be effective for the control of osteoporosis, particularly in individuals who have been subjected to thyroidectomies/ parathyroidectomies. Therapeutic dosages of PTH will, in some individuals, result in unacceptable diminution of blood pressure and may result in relaxation of smooth muscles such as gastrointestinal, uterus, tracheal, vas deferens as well as exhibit positive chronotropic and inotropic effects on the heart. To avoid hypotensive effects, smooth muscle relaxation effects and positive chronotropic and inotropic effects on the heart, it was envisaged that the structure of PTH could be modified to decouple the hypotensive, smooth muscle relaxation and positive chronotropic and inotropic function from the bond calcium and bone deposition function. It has now been discovered that a critical site exists at amino acid twenty-five, twenty-six and twenty-seven, which is -Arg-Lys-Lys- in both bovine and human PTH. Substitution at the -Arg-Lys-Lys- site with -Ala-Ala-Ala- diminishes the hypotensive as well as smooth muscle relaxation and positive chronotropic and inotropic effects without denigrating from the osteo effect. These results suggest that substitution at the -Arg-Lys-Lys- site with amino acids other than basic amino acids arginine and lysine would also diminish the hypotensive, smooth muscle relaxation and positive chronotropic and inotropic effects without denigrating from the osteo effect.

The procedure of Erickson and Merrifield, as modified by Hodges et al., as described above, may be used to synthesize

synthetic PTH or fragments thereof. The procedure enables substitution for the naturally occurring PTH at substantially every location and it is possible to prepare both bovine and human synthetic PTH at full length or in the sequence of the first thirty-four amino acids, which is more facilely performed. Such substitution can also be accomplished by genetic engineering.

Substitution at position twenty-five, twenty-six and twenty-seven invariably alters the observed hypotensive, smooth muscle relaxation and positive chronotropic and inotropic effects, whether the full length PTH or the 1-34 fragment is administered. Substitution of -Ala-Ala-Ala- for -Arg-Lys-Lys- at position twenty-five, twenty-six and twenty-seven is particularly preferred because the change in blood pressure, smooth muscle relaxation and positive chronotropic and inotropic effects from this substitution are minimal and calcium uptake, as measured in osteoblasts, mimics the results from the administration of native PTH. The 1-34 PTH fragment with $-Ala^{25}-Ala^{26}-Ala^{27}-$ is particularly preferred because the pharmacological properties are those which are desired and the difficulty of synthesis is minimized. Synthesis of the compounds used in the development of this invention was performed at Alberta Peptide Institute (API) and the cooperation of API is gratefully acknowledged.

The structure of bovine parathyroid hormone (bPTH) and human parathyroid hormone (hPTH) are shown in Figs. 1a (SEQ ID NO:1) and 1b (SEQ ID NO:2). Representative synthetic analogues are described in Table 1 and are further shown in Figs. 2-9 and SEQ ID NO:3-SEQ ID NO:10. The hypotensive effects of these analogues is shown in Figs. 10, 11, 15 and 19. All of the analogues produce either no or less diminution of blood pressure than does native PTH. With only one amino acid at either the 25, 26 or 27 position substituted, the analogue shows less effect than native PTH. With all three positions substituted, it provides almost no change. At the level of 5 μg/kg of PTH, the blood pressure in Sprague-Dawley rats is such that they are essentially moribund.

We have developed a method for modeling the hypotensive effects of natural and synthetic chemical compounds using helically cut tail arteries from Sprague-Dawley rats in a Sawyer-Bartlestone chamber, measuring the change in tension with a force displacement transducer. This method and the effect of bovine PTH-(1-34) in this system is described in Blood Vessels, 22, 57 (1985). It is demonstrated in this paper that bPTH-(1-34) produces dose-dependent relaxation of helical strips of rat tail artery which have been previously contracted by arginine-vasopressin (AVP). Figs. 12, 16 and 20 illustrate the effect of the PTH analogues of this invention as measured using this in vitro technique. Alternatively, the strips may be precontracted using other pressor substances such as norepinephrine (NE) or KCl.

We have also developed a method of modeling the chronotropic effects of natural and synthetic chemicals using the right atrium from Sprague-Dawley rats and measuring the change in the force and rate of atrium contraction. This method and the effects of bovine PTH (1-34) in this system are described in Tenner et al, The Canadian Journal of Physiology and Pharmacology, Volume 61, No. 10 (1983) pp. 1162-1167. It is demonstrated in this paper that bPTH (1-34) produces significant dose-dependent chronotropic effects on rat cardiac pacemaker tissue. Figs. 24-25 illustrate the effect of the PTH analogues of this invention as measured using this in vitro technique.

Because osteoporosis is a progressive syndrome, a model is required and the use of cultured osteoblasts of the UMR-106 rat osteosarcoma cells, ATCC CRL 1661 have been used as the model. Uptake of calcium in these cells has been monitored using the FURA-2 method, wherein a fluorescent dye which is specific for calcium is used as a marker for calcium change into the cells. Cells are incubated with 1-10 μM of the acetomethoxy ester of FURA-2 for 30-60 minutes. Upon uptake, the ester is hydrolyzed to release free FURA-2, which selectively binds free Ca^{2+}. FURA-2 has a characteristic fluorescence spectrum, which wavelength is shifted when the dye binds to free Ca^{2+}.

According to the method, Ca^{2+} which is present in the cell can be quantified by exciting the dye at two different wavelengths, 340 and 380 nm. The emission fluorescence is measured at 510 nm. The calcium concentration is proportional to the ratio of the fluorescent emission when excited at 340 nm to the emission at 380 nm. It is conventional to report the concentration of calcium within the cell in terms of the fluorescence ratio, the 340/380 ratio. This technique is described in Grynkiewicz et al., J. Biol. Chem., 260, 3440 (1985) and Pang et al., P. N. A. S. (USA), 87, 623 (1990).

Figs. 13, 14 a-d, 17, 18, 21, 22 and 23 illustrate the results of the above-described measurements when inhibitors such as an anti-osteoporotic agent (788) or bPTH-(1-34) or Cs114 were used in the presence of KCl.

As can be readily seen from the figures, the PTH analogues, whether full length or 1-34, which contain anomalous amino acids at positions twenty-five, twenty-six and twenty-seven (most particularly those which contain Ala^{25}-Ala^{26}-Ala^{27}), do not effect a hypotensive and smooth muscle relaxation response, including positive chronotropic effects, but do inhibit calcium uptake as stimulated by KCl in osteoblasts, which indicates that these compounds would have the same effect on bone cells as PTH and would be useful in the treatment of osteoporosis in mammals and, particularly, in man, without the aformentioned deleterious side effects in the elderly.

While not being bound by any theory, it is suggested that substitution Arg^{25}-Lys^{26}-Lys^{27} by other amino acids in 1-84 PTH and in the 1-34 analogues removes the vasodepressor, smooth muscle relaxation and positive chronotropic and inotropic effects of either bPTH or hPTH. The effect on KCl induced calcium uptake in osteoblasts, however, is essentially unchanged for 1-84 or 1-34 PTH. In other words, the effect on bone cells is unchanged from PTH.

The physiological significance of an inhibiting effect on the KCL induced calcium uptake in bone cells is not yet understood. One hypothesis is that the analogues interact

fully with bone cell receptor activity. The fact that the same effect is seen for both PTH and the analogues disclosed herein suggests that the site of interaction with the osteoblast cell receptor is unchanged by the substitution.

The analogues of the present invention can be used in the treatment of osteoporosis and other bone related diseases and disorders involving bone cell calcium regulation.

The analogues of the present invention may be administered to a warm-blooded mammalian in need thereof, particularly a human, by parental, topical, rectal administration or by inhalation. The analogues may be conventionally formulated in a parenteral dosage form compounding about 1 to about 300 mg per unit of dosage with a conventional vehicle, excipient, binder, preservative, stabilizer, color, agent or the like as called for by accepted pharmaceutical practice.

For parental administration, a 1 to 10 ml intravenous, intramuscular or subcutaneous injection would be given one to four times daily. The injection would contain an analogue of the present invention in an aqueous isotonic sterile solution or suspension optionally with a preservative such as phenol or a solubilizing agent such as ethylenediaminetetraacetic acid (EDTA). Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Synthetic monoglycerides, diglycerides, fatty acids (such as oleic acid) find use as fixed oil in the preparation of injectables.

For rectal administration, the analogues of the present invention can be prepared in the form of suppositories by mixing with a suitable non-irritating excipient such as cocoa butter or polyethylene glycols.

For topical use, the analogues of the present invention can be prepared in the form of ointments, jellies, solutions, suspensions or dermal adhesive patches.

In a powdered aerosol, analogues of the present invention may be administered by a spinhaler turbo-inhaler device

obtained from Fisons Corporation of Bedford, Massachusetts, at a rate of about 0.1 to 50 mg per capsule, 1 to 8 capsules being administered daily for an average human. In a liquid aerosol, the compounds of the present invention are administered at the rate of about 100 to 1000 micrograms per "puff" or activated release of a standard volume of propellant. The liquid aerosol would be given at the rate of 1 to 8 "puffs" per day with variation in dosages due to the severity of the conditions being treated, the weight of the patient and the particle size distribution of the aerosol. A fluorinated hydrocarbon or isobutane find use as propellants for liquid aerosols.

Daily doses are in the range of about 0.01 to about 200 mg per kg of body weight, depending on the activity of the specific compound, the age, weight, sex and conditions of the subject to be treated, the type and severity of the disease, the frequency and route of administration. As would be well known, the amount of active ingredient that may be combined with the carried materials to produce a single dosage will vary depending upon the host treated and the particular mode of administration.

The following examples demonstrate the utility of applicants' invention. The examples are not limiting, but are illustrative only, and modifications which would be apparent to those skilled in the art are included within the scope of this disclosure.

Example 1

In Vivo Blood Pressure Measurement.

Sprague-Dawley (S-D) rats were anaesthetized with pentobarbital and a cannula was inserted into the carotid artery. The rats were kept sedated during the procedure and were injected with PTH peptides only when the blood pressure of the rats were stable. Peptides were injected through a cannula in the jugular vein, in amounts of 1, 3 and 5 or more μg/kg and the mean systolic and diastolic blood pressure was monitored continuously throughout the procedure. Results are reported with comparison to bPTH-(1-34).

Example 2

In Vitro Rat Tail Artery Helical Strip Tension Assay

The assay was performed according to Pang et al., Blood Vessels, 22, 57 (1985). Sprague-Dawley rats were anaesthetized with pentobarbital and the tail artery excised and placed in ice-cold Krebs-Hanseleit solution (KHS) oxygenated with 95% O_2, 5% CO_2. Each artery was cut helically and strips of approximately 1.5 cm were secured in a Sawyer-Bartlestone chamber containing KHS. The force generated by the strips was measured with a Grass FT03 force displacement transducer and recorded on a polygraph. Isolated tail artery helical strips were equilibrated for 1 hour prior to use.

One to two minutes prior to addition of a peptide, the strips were contracted by addition of either arginine vasopressin (AVP), potassium chloride (KCl) or norepinephrine (NE) to the bath. The peptide was then added to the bath and the degree of relaxation measured. Bovine serum albumin was used as a control. Results are reported as percent decrease in tension for each drug and dose used. Drug dose is calculated on the basis of the final concentration in the bath solution.

Example 3

In Vitro atrial contractility and contraction rate measurement

The assay was performed according to Tenner et al., Canadian Journal of Physiology and Pharmacology, Vol. 61, No. 10 (1983) pp. 1162-1167. Sprague-Dawley rats weighing between 100 and 250 g were treated with heparin (500 IU, i.p.) 15 minutes prior to decapitation. Thoracotomies were performed and the heart rapidly excised and placed in a cold physiological salt solution (PSS) having the following composition (in millimolar): NaCl, 120; KCl, 5.63; $CaCl_2$, 2.0; $MgCl_2$, 2.1; $NaHCO_3$, 25.0; dextrose, 9.7. The solution was continously aerated by a gas mixture of 95% O_2-5% CO_2. The right atrium was isolated and suspended in a tissue chamber containing 20 mL of PSS at 37°C, pH 7.4. Atria were allowed to equilibrate for 1 hr under a resting tension of 1 g.

The atrial rate and force were determined from

contractions recorded by a Grass FT.03 force-displacement transducer and a Grass model 79 polygraph. The Basial atrial rate for control atria (as determined by counting the frequency of contractions) was 258 ± 7 bpm (n=29). Basal developed force of the spontaneously beating right atria was 0.33 ± 0.06 g (n=10). Dose-response curves for the peptides were obtained by cumulative addition of the respective peptides. Drug dose is calculated on the basis of the final concentration in the bath solution.

Example 4

Measurement of Intracellular Free Calcium Concentration In Vitro

Intracellular free calcium concentration was measured using the fluorescent dye FURA-2 according to the method of Grynkiewicz et al., J. Biol. Chem., 260, 3440 (1985) and Pang et al., P. N. A. S. (USA), 87, 623 (1990). UMR-106 rat osteosarcoma cells (ATCC CRL-1661) are incubated in 1-10 μM FURA-2 AM (Sigma Chemical Co., St. Louis), the acetomethoxy ester of FURA-2. Upon hydrolysis within the cell, FURA-2 is released which selectively binds to free Ca^{2+}. Binding to Ca^{2+} shifts the fluorescent spectrum of FURA-2. Quantitation is obtained by exciting the dye at two different wavelengths, preferably 340 and 380 nm and measuring the fluorescent emission at 510 nm. The concentration of calcium is proportional to the ratio of the fluorescence emitted at 340 nm to that at 380 nm.

KCl is used in the medium to stimulate $[Ca^{2+}]_i$ increase.

After the intracellular $[Ca^{2+}]_i$ had been measured, the cells were washed with the original medium and the analogues added and the intracellular $[Ca^{2+}]_i$ measured again. KCl was then added without washing to measure the effect of the analogue on KCl induced $[Ca^{2+}]_i$ changes. After measurement, the cells were washed with the medium 3-4 times and KCl again added to determine the recovery of the cells after removal of the analogue. Results are shown by actual traces and histograms summarizing the results. As can be seen from Figs.

14 a-d, PTH inhibits intracellar $[Ca^{2+}]_i$ increases as stimulated by KCl and measured by the method. Figs. 18, 21, 22 and 23 illustrate comparable results for the $aa^{25,26,27}$ analogues.

The comparability of the analogues and PTH itself is considered to indicate that the analogues would be as useful as PTH for the treatment of osteoporosis.

Table I

Designation	Length	Source	Substitution	Site
Cs88	1-34	bovine	none	
Cs99	1-34	bovine	Ala	25
Cs100	1-34	bovine	Ala	26
Cs117	1-34	bovine	Ala	27
Cs 221	1-34	human	Ala	25,26,27
Cs1001	1-34	human	none	
Cs2001	1-84	human	none	

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: PANG, Peter K.T.
JIE, Shan

(ii) TITLE OF INVENTION: PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT AA $^{25, 26, 27}$ AND USE IN OSTEOPOROSIS TREATMENT

(iii) NUMBER OF SEQUENCES: 10

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Nikaido, Marmelstein, Murray & Oram
(B) STREET: 655 Fifteenth Street N.W., Suite 330
(C) CITY: Washington D.C.
(D) STATE:
(E) COUNTRY: United States of America
(F) ZIP: 20005-5701

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 773,098
(B) FILING DATE: 10-Oct-91
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Murray, Robert B.
(B) REGISTRATION NUMBER: 22,890
(C) REFERENCE/DOCKET NUMBER: 1610-2002

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (202) 638-5000
(B) TELEFAX: (202) 638-4810

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His
1 5 10

Leu Ser Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10

Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His
1 5 10

Leu Ser Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu
15 20 25

Gln Asp Val His Asn Phe
30

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His
1 5 10

Leu Ser Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu
15 20 25

Gln Asp Val His Asn Phe
30

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10

Leu Asn Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu
15 20 25

Gln Asp Val His Asn Phe
30

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10

Leu Asn Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu

15 20 25

Gln Asp Val His Asn Phe

30

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His

1 5 10

Leu Ser Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu

15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala

30 35 40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp

45 50 55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala

60 65 70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln

75 80

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His
1 5 10

Leu Ser Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu
15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10

Leu Asn Ser Met Glu Arg Val Glu Trp Leu Xaa Xaa Xaa Leu
15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 84 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
1 5 10

Leu Asn Ser Met Glu Arg Val Glu Trp Leu Ala Ala Ala Leu
15 20 25

Gln Asp Val His Asn Phe Val Ala Leu Gly Ala Ser Ile Ala
30 35 40

Tyr Arg Asp Gly Ser Ser Gln Arg Pro Arg Lys Lys Glu Asp
45 50 55

Asn Val Leu Val Glu Ser His Gln Lys Ser Leu Gly Glu Ala
60 65 70

Asp Lys Ala Asp Val Asp Val Leu Ile Lys Ala Lys Pro Gln
75 80

CLAIMS

1. A bovine parathyroid hormone analogue comprising the structure shown in SEQ ID NO:3, wherein each of Xaa^{25}, Xaa^{26} and Xaa^{27} is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenyalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

2. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:4.

3. A human parathyroid hormone analogue comprising the structure shown in SEQ ID NO:5, wherein each of Xaa^{25}, Xaa^{26} and Xaa^{27} is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenyalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

4. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:6.

5. A bovine parathyroid hormone analogue comprising the structure shown in SEQ ID NO:7, wherein each of Xaa^{25}, Xaa^{26} and Xaa^{27} is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenyalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

6. The bovine parathyroid hormone analogue having the structure shown in SEQ ID NO:8.

7. A human parathyroid hormone analogue comprising the structure shown in SEQ ID NO:9, wherein each of Xaa^{25}, Xaa^{26} and Xaa^{27} is Alanine (Ala), Asparagine (Asn), Aspartic acid (Asp), Cysteine (Cys), Glutamine (Gln), Glutamic acid (Glu), Glycine (Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Methionine (Met), Phenyalanine (Phe), Proline (Pro), Serine (Ser), Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr) or Valine (Val).

8. The human parathyroid hormone analogue having the structure shown in SEQ ID NO:10.

9. A pharmaceutical composition comprising a PTH analogue according to any one of claims 1-8 and a pharmaceutically acceptable carrier.

10. A method of treatment of osteoporosis in a patient in need of such treatment without causing substantial induction of hypotension, smooth muscle relaxation and cardiac inotropic and chronotropic action, said method comprising administering an osteoporotic effective amount of a PTH analogue according to any one of claims 1-8.

Fig. 1a

H_2N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO_2H

Fig. 1b

H_2N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO_2H

Fig. 2

H_2N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-CO_2H

Fig. 3

H_2N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-CO_2H

Fig. 4

H_2N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-CO_2H

Fig. 5

H_2N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-CO_2H

Fig. 6

H_2N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO_2H

Fig. 7

H_2N-Ala-Val-Ser-Glu-Ile-Gln-Phe-Met-His-Asn-Leu-Gly-Lys-His-Leu-Ser-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO_2H

Fig. 8

H_2N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Xaa-Xaa-Xaa-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO_2H

Fig. 9

H_2N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Ala-Ala-Ala-Leu-Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Ser-Ile-Ala-Tyr-Arg-Asp-Gly-Ser-Ser-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Glu-Ser-His-Gln-Lys-Ser-Leu-Gly-Glu-Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Ile-Lys-Ala-Lys-Pro-Gln-CO_2H


EFFECT OF PTH ANALOGES ON D.B.P IN SD
n = 8
CS99
CS100
CS117
PTH
*P≤0.05, ** P<0.01
DRUGS (ug/kg)
0
1
2
3
4
5
110
94
78
62
46
30
DIASTOLIC BLOOD PRESSURE (mmHg)

FIG. 10


EFFECT OF PTH ANALOGES ON S.B.P. IN SD n=8
CS99
CS100
CS117
PTH
* P<0.05, ** P<0.01
DRUGS (ug/kg)
SYSTOLIC BLOOD PRESSURE (mmHg)
110
95
80
65
50
35
0
1
2
3
4
5

FIG. 11


Ralaxation Effect of PTH Analoges on
Rat Tail Artery Elicited by AVP (n=4)
PTH
08117
0899
08100
Relaxation % Decrease in Tension
100
80
60
40
20
0
0
0.01
0.03
0.1
0.3
1
Drugs Log(ug/ml)

Fig. 12


A KCL 15mM
B 788 2*10-5M
C KCL 15mM AFTER 788 10m
D KCL 15mM AFTER 788 20m
A
B
C
D
3.0000
2.6250
2.2500
1.8750
1.5000
0
100
200
300
400
500
600
TIME (sec)
RATIO

FIG. 13



FIG. 14a



FIG. 14c



FIG. 14b



FIG. 14d


EFFECT OF CS88 ON BLOOD PRESSURE OF
ANESTHETIZED SD RATS (n = 8)
bPTH(1-34)
139±6mmHg
20
0
-20
-40
-60
-80
-100
0
1
2
3
4
5
6
BLOOD PRESSURE CHANGE (mmHg)
DRUG (ug/kg)

FIG. 15


DOSE RELATED RELAXATION CURVES PRODUCED BY DRUG bPTH (1-34)
ON SD RAT TAIL ARTERY HELICAL STRIPS PRECONTRACTED WITH KCL
(60mM), NE (3x10⁻⁶M) OR AVP(10⁻⁸M)
KCL (n=4)
775±22mg
NE (n=4)
821±25mg
AVP (n=4)
1162±80mg
20
0
-20
-40
-60
-80
-100
CHANGE IN TENSION (%)
.005
.01
0.1
1
bPTH(1-34) (ug/ml)

FIG. 16


EFFECT OF CS88 ON KCL STIMULATED INTRACELLULAR FREE CALCIUM CONCENTRATION IN CULTURED UMR OSTEOBLAST CELLS
ACTUAL TRACING OF ONE REPRESENTATIVE EXPERIMENT
A CONTROL KCL 15mM
B PTH 2.5 x 10-6M
C KCL 15mM AFTER PTH 10MIN
D KCL 15mM AFTER WASH
A
B
C
D
6.7670
5.0759
3.3839
1.6920
0.0000
0
100
200
300
400
500
600
TIME (sec)
INTRACELLULAR CALCIUM AS RATIO OF FLUORESCENCE (510nM) INTENSITY
(EXCITATION WAVELENGTH AT 340 nM AND 380 nM)

FIG.17


EFFECT OF CS88 ON INTRACELLULAR
CALCIUM INCREMENT INDUCED BY KCL IN UMR
CONTROL KCL 15mM
CS88 3 uM
KCL 15 mM
*
* P<0.05
120
100
80
60
40
20
0
INTRACELLULAR CALCIUM INCREMENT %

FIG. 18


DOSE RESPONSE CURVES OF BLOOD PRESSURE IN SD RATS.
THE BLOOD PRESSURE CHANGE BY VEHICLE SALINE
IN 0 mmHg n=4
CS221 133±6.3 mm Hg
Cg99 105±10 mm Hg
PTH-(1-34) 120±5.6 mm Hg
60
24
-12
-48
-84
-120
CHANGE IN BLOOD PRESSURE mm Hg
.003
.01
0.1
1
10
CS COMPOUNDS (ug/kg)

FIG. 19


DOSE RELATED RELAXATION CURVES IN SD RAT TAIL ARTERY HELICAL STRIPS PRECONTRACTED WITH AVP (10-8 M)
CS221 875±7 mg
CS99 812±11 mg
CS100 868±12 mg
CS117 850±10mg
CS88 1162±8mg
20
0
-20
-40
-60
-80
-100
CHANGE IN TENSION (%)
.005
.01
0.1
1
CS COMPOUNDS (ug / ml)

FIG. 20


EFFECTS OF hPTH-(1-34) AND CS221 ON INTRACELLULAR CALCIUM INCREMENT INDUCED BY KCl 15mM IN UMR CELLS
CS221 (n=4)
hPTH (1-34) (n=4)
* P<0.01
CS COMPOUNDS (ug/ml)
CHANGE IN RATIO (%)
0
-10
-20
-30
-40
-50
-60
.05
0.1
1
10

FIG. 21


EFFECT OF CS 221 ON INTRACELLULAR CALCIUM INCREMENT IN UMR BONE CELLS
CONTROL KCL 15mM
CS 221 0.1 ug/ml
CS 221 1ug/ml
CS 221 3ug/ml
* P<0.01
120
100
80
60
40
20
0
INTRACELLULAR CALCIUM INCREMENT %

FIG. 22


EFFECT OF CS 1001 ON INTRACELLULAR CALCIUM INCREMENT IN UMR(106)
CONTROL KCL 30mM
CS1001 1UG/ML
* P<0.05, MEAN VALUE OF FIVE CELLS
2.00
1.60
1.20
.80
.40
0
INTRACELLULAR CALCIUM INCREMENT RATIO

FIG. 23


DOSE RELATED RESPONSE CURVES OF RIGHT ATRIAL (SD RAT)
CONTRACTILITY AND CONTRACTION RATE BY DRUG CS221
CONTRACTION RATE
318.8+9.2 BEATS/MIN (n=4)
CONTRACTILITY
234.4+31.2 mg (n=4)
CHANGE IN FORCE AND RATE (%)
200
180
160
140
120
100
80
60
40
20
0
DRUG CS221 (ug/ml)
.002
.01
0.1
1

FIG. 24


DOSE RELATED RESPONSE CURVES OF RIGHT ATRIAL (SD RAT)
CONTRACTILITY AND CONTRACTION RATE BY DRUG CS1001 CS2001
CS1001 RATE
CS2001 RATE
CS1001 FORCE hPTH-(1-34)
CS2001 FORCE hPTH-(1-84)
CHANGE IN FORCE AND RATE (%)
200
180
160
140
120
100
80
60
40
20
0
10
100
1000
10000
DRUG CS1001 CS2001 (10^{-10}M)

FIG. 25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/08477

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 37/02, 37/36; C07K 7/10
US CL :530/324, 399; 514/12
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/324, 399; 514/12, 2, 21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS (Parathyroid and Osteoporosis)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,833,125 (NEER ET AL.) 23 May 1989, see the entire document, particularly the Abstract.	1-10
Y	US, A, 4,086,196 (TREGEAR) 25 April 1978, see the entire document, particularly the Abstract.	1-10
Y	US, A, 4,771,124 (ROSENBLATT ET AL.) 13 September 1988, see the entire document, particularly the Abstract.	1-10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
18 DECEMBER 1992	12 JAN 1993
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer FATEMEH T. MOEZIE VSH
Facsimile No. NOT APPLICABLE	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*